Low molecular weight heparin and atherosclerosis

被引：0
作者：
Hunt D. [1 ]
机构：
[1] Section of General Internal Medicine, Ben Taub General Hospital, Houston, TX 77030
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 2期
关键词：
Percutaneous Coronary Intervention; Acute Coronary Syndrome; Enoxaparin; Abciximab; Unfractionated Heparin;
D O I：
10.1007/s11883-004-0103-9
中图分类号：
学科分类号：
摘要：
Low molecular weight heparin (LMWH) has dramatically impacted the treatment of venous thromboembolic disease and acute coronary syndromes. Recent studies help define the role of these agents for patients undergoing percutaneous coronary interventions and for patients treated with thrombolytic agents for ST-segment elevation myocardial infarction. Recent studies also suggest potential usefulness of LMWH for patients with peripheral vascular disease and its limits of utility in stroke. This review summarizes the evidence about the use of LMWH in these clinical situations. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：140 / 147
页数：7
相关论文
共 46 条
  • [1] Wallentin L., Low-molecular-weight heparins in coronary thrombosis: Today and tomorrow, Haemostasis, 29, SUPPL. 1, pp. 32-37, (1999)
  • [2] Antman E.M., Cohen M., Newer antithrombin agents in acute coronary syndromes, Am. Heart J., 138, 6 PART 2, (1999)
  • [3] Levine G.N., Ali M.N., Schafer A.I., Antithrombotic therapy in patients with acute coronary syndromes, Arch. Intern. Med., 161, pp. 937-948, (2001)
  • [4] Hirsh J., Warkentin T.E., Shaughnessy S.G., Et al., Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest, 119, SUPPL. 1, (2001)
  • [5] White R.H., Ginsberg J.S., Low-molecular-weight heparins: Are they all the same?, Br. J. Haematol., 121, pp. 12-20, (2003)
  • [6] Eikelboom J.W., Anand S.S., Malmberg K., Et al., Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis, Lancet, 355, pp. 1936-1942, (2000)
  • [7] Braunwald E., Antman E.M., Beasley J.W., Et al., ACC/AHA guideline updated for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 106, pp. 1893-1900, (2002)
  • [8] Gurfinkel E.P., Manos E.J., Mejail R.I., Et al., Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia, J. Am. Coll. Cardiol., 26, pp. 313-318, (1995)
  • [9] Wallentin L., Lagerqvist B., Husted S., Et al., Outcome at 1 year after in invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial, Lancet, 356, pp. 9-16, (2000)
  • [10] Low-molecular-weight heparin during instability in coronary artery disease, Lancet, 347, pp. 561-568, (1996)
12345